Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)
From Oncology Brothers: Practice-Changing Cancer Discussions · · 22 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.
Key topics discussed included:
- The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies
- The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma
- Treatment selection based on patient age, prior therapy, drug exposure, and disease biology
- The importance of shared decision-making and incorporating patient preferences into treatment planning
- Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care
This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
- X/Twitter: https://x.com/oncbrothers
- Instagram: https://www.instagram.com/oncbrothers
- Website: https://oncbrothers.com/
Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology.
#MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem